12
December 2022
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer at SABCS 2022
The median OS was not reached with 12, 18 and 24 months OS rates at 93.0 %, 91.2 % and 91.2 %, respectively.